Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.25
-0.13 (-0.90%)
Mar 3, 2026, 4:00 PM EST - Market closed
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 87.27B INR in the quarter ending December 31, 2025, with 4.40% growth. This brings the company's revenue in the last twelve months to 346.33B, up 11.06% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
346.33B INR
Revenue Growth
+11.06%
P/S Ratio
3.06
Revenue / Employee
12,452,806 INR
Employees
27,811
Market Cap
11.76B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | 153.85B | 11.82B | 8.32% |
| Mar 31, 2018 | 142.03B | 1.22B | 0.87% |
| Mar 31, 2017 | 140.81B | -13.90B | -8.98% |
| Mar 31, 2016 | 154.71B | 6.52B | 4.40% |
| Mar 31, 2015 | 148.19B | 16.02B | 12.12% |
| Mar 31, 2014 | 132.17B | 15.90B | 13.68% |
| Mar 31, 2013 | 116.27B | 19.53B | 20.19% |
| Mar 31, 2012 | 96.74B | 22.04B | 29.51% |
| Mar 31, 2011 | 74.69B | 4.42B | 6.28% |
| Mar 31, 2010 | 70.28B | 836.00M | 1.20% |
| Mar 31, 2009 | 69.44B | 19.44B | 38.87% |
| Mar 31, 2008 | 50.01B | -15.09B | -23.18% |
| Mar 31, 2007 | 65.10B | 40.83B | 168.24% |
| Mar 31, 2006 | 24.27B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Viatris | 14.30B |
| Elanco Animal Health | 4.72B |
| United Therapeutics | 3.18B |
| Amneal Pharmaceuticals | 3.02B |
| Neurocrine Biosciences | 2.86B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
RDY News
- 5 days ago - Top losers among Nifty 50 stocks in midday trades today, Feb 27: Dr. Reddy’s falls 2.8%, Bharti Airtel down 2.7%, Grasim Industries drops 2.5% - Business Upturn
- 5 days ago - Pharma sector stocks today, Feb 27: Dr. Reddys Lab down 1.14%, Cipla falls 1.04%, Natco Pharma up 1.09% - Business Upturn
- 7 days ago - Citi flags Ozempic price cuts as negative for Dr Reddy’s generic Semaglutide uptake - Business Upturn
- 11 days ago - Dr. Reddy's (RDY) Biosimilar Application for Orencia Accepted by FDA - GuruFocus
- 11 days ago - Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept - Business Wire
- 13 days ago - Dr. Reddy’s Laboratories acquires Progynova and Cyclo-Progynova trademarks in India for $32.15 million - Business Upturn
- 22 days ago - Top losers among Nifty 50 stocks in midday trades today, Feb 10: Shriram Finance, Bajaj Finance, Dr. Reddy’s, SBI Life and more - Business Upturn
- 4 weeks ago - India-US trade deal clarity: Pharma exporters gain edge in US; sector eyes growth boost - The Times of India